You are here: Industry Insights > Lung

News List

GSK chases Trelegy asthma nod with mixed phase 3 results fiercepharma
May 06, 2019
With generics attacking Advair, GlaxoSmithKline has talked up prospects for 3-in-1 respiratory med Trelegy. Now, the company has data in hand that could help it move into the asthma arena—though it's not all positive.
RNA-based therapy cures lung cancer europeanpharmaceuticalreview
April 25, 2019
By turning down the activity of a specific RNA molecule, researchers have cured lung tumours in mice…
Moleculin Announces Significant Discovery in Lung Cancer Models americanpharmaceuticalreview
April 22, 2019
Moleculin Announces Significant Discovery in Lung Cancer Models...
Study shows CRISPR could help treat lung disease in utero pharmaceutical-technology
April 22, 2019
Study shows CRISPR could help treat lung disease in utero.
Artificial intelligence improves diagnosis of lung disease: study europeanpharmaceuticalreview
April 18, 2019
Diagnosing lung disease using AI was found to be accurate in twice as many cases as the diagnosis of pulmonologists…
Durvalumab improves survival of non-small cell lung cancer patients europeanpharmaceuticalreview
April 18, 2019
Moffitt researchers conducted a Phase III trial which found durvalumab to increase the survival of patients with non-small cell lung cancer…
Leicester to support chronic lung disease sufferers globally europeanpharmaceuticalreview
April 17, 2019
“We will work with health care professionals and patients to develop a form of rehabilitation that will be acceptable to all those involved.”
Leicester to support chronic lung disease sufferers globally europeanpharmaceuticalreview
April 17, 2019
“We will work with health care professionals and patients to develop a form of rehabilitation that will be acceptable to all those involved.”
Keytruda continues its lung cancer land grab with another FDA nod fiercepharma
April 15, 2019
Solo therapy with Merck & Co.’s Keytruda is already approved in previously untreated non-small cell lung cancer patients with high levels of the PD-L1 biomarker.
Vertex’ three-drug CF combo hits PhIII targets pharmatimes
March 08, 2019
Vertex’ three-drug cystic fibrosis regimen – combining the investigational next-generation corrector VX-445 with Kalydeco (ivacaftor) and tezacaftor – has achieved primary endpoints of two Phase III studies in patients the condition.

Previous page 1 2 3 4 5 6 7 8 9 Next page